The current regulatory framework leaves 503A pharmacies largely untracked, as they fall outside the mandatory reporting requirements imposed on major drug manufacturers and 503B outsourcing facilities. Without a centralized system, incidents of patient harm frequently remain isolated within a single state, preventing regulators from identifying broader safety trends. Executive director Lemrey “Al” Carter emphasized that regulators cannot mitigate risks they cannot see, noting that a unified database will allow a single reported harm to trigger proactive protections for patients nationwide.

This initiative arrives as the compounding industry faces pressure from a surge in GLP-1 medications, a shift that has outpaced existing oversight models. Beyond the clearinghouse, the Association plans to establish model standards for verifying bulk drug substances and create formal referral pathways between pharmacy boards, medical boards, and state attorneys general. In the coming months, the NABP will convene with the FDA and industry stakeholders to finalize the design and governance of the new reporting infrastructure.